Overview
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co., Inc.

Oncology Best Practice™: Honing Patient Management Approaches with PARP Inhibition in Ovarian Cancer: What Nurses Need to Know

Oncology Best Practice™: Honing Patient Management Approaches with PARP Inhibition in Ovarian Cancer: What Nurses Need to Know


Oncology Best Practice™: Honing Patient Management Approaches with PARP Inhibition in Ovarian Cancer: What Nurses Need to Know

In order to request this CME/CE activity for your center, please contact Samantha Zelasko at SZelasko@gotoper.com

Overview

Oncology Best Practice™ is a series of interactive meetings hosted by leading cancer centers, large oncology practice groups, and community hospitals throughout the United States. Each meeting will be led by a nationally renowned nurse with expertise in ovarian cancer. The live session begins with a brief overview of PARP inhibition in ovarian cancer, including the rationale and indications for use of this drug class. Subsequently, the program will focus on key practical and patient-focused issues related to PARP inhibitor use, including dosage and administration; optimized communication, counseling and education; and best practices for timely identification and management of adverse events. This program is designed to address common clinical challenges encountered in the community setting when using PARP inhibitor therapy to treat patients with advanced ovarian cancer in the primary or relapsed/refractory setting.

Benefits of Participating

  • Interact with a nationally recognized ovarian cancer expert and local peers at each meeting
  • Gain practical information about use of PARP inhibitors that you can immediately apply to your practice
  • Develop strategies for managing adverse events associated with PARP inhibition for your patients
  • Learn how to counsel your patients about PARP inhibitor therapy

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck & Co., Inc.

Target Audience

This educational activity is directed toward advanced practitioners, nurses, and other health care professionals interested in the multidisciplinary treatment and management of ovarian cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Summarize safety and efficacy data pertaining to the application of current and emerging PARP inhibitors in the setting of ovarian cancer
  • Formulate a plan of care to manage and mitigate the impact of adverse events associated with PARP inhibitor therapy
  • Outline patient and disease factors that play a role in determining appropriate PARP inhibitor treatment strategies
  • Identify effective counseling strategies to educate patients who may be candidates for PARP inhibitor therapy regarding safety and efficacy

Program Chair

Paula Anastasia RN, MN, AOCN
Paula Anastasia RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
Dept of OB/GYN
UCLA Health
David Geffen School of Medicine
Los Angeles, CA
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By